Clinical implementation of an uveitis prediction model
Suspended
- Conditions
- on-infectious uveitis for at least 3 months.
- Registration Number
- NL-OMON23206
- Lead Sponsor
- Oogziekenhuis Rotterdam (OZR)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 250
Inclusion Criteria
Non-infectious uveitis for at least 3 months.
- Age ≥ 18 years.
Exclusion Criteria
- Major eye condition preventing any VA improvement or reduction (such as end stage glaucoma, end stage corneal diseases, end stage macular degeneration).
- Suspected or proven infectious uveitis.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of visual acuity between entry and 12 months.
- Secondary Outcome Measures
Name Time Method - Duration and dosage of immunosuppressive medication.<br /><br>- Change of inflammatory activity between entry and at 12 months.<br /><br>- Difference between predicted and achieved VA at 12 months.<br /><br>- Accuracy of predicted VA.<br /><br>- Difference between predicted and actual inflammatory activity at 12 months.<br /><br>- Accuracy of predicted activity.<br /><br>- Complications.<br /><br>- VFQ-25.<br /><br>- Change of outcomes for individual eyes as predicted by the model during the course of the 12 months follow up.<br /><br>- Change of prediction model perfomance (with respect to legal driving visual acuity, low vision, legal blindness) by means of internal validation.<br /><br>- IOP.<br /><br>- OCT.<br /><br>- The clinician's appraisal of the influence of the predictive model information on the prescribed therapy dosages.<br /><br>